We are committed to launching companies steeped in world-class science, drug discovery, and cancer drug development.

Treadwell Therapeutics
Treadwell Therapeutics is a clinical-stage oncology company exploiting cancer cells’ vulnerabilities to develop first-in-class and best-in-class small molecules to address unmet needs in patients with highly aggressive cancers. Harnessing unique innovations from founders, partners, and TIO Discovery, the company is advancing a pipeline of novel clinical candidates with pan-cancer potential aimed at genomic instability and previously untapped immuno-oncology targets.

We have also targeted several additional start-ups with assets from our TIO Discovery group, including an immuno-oncology company focused on a novel approach to T cell therapeutics and a biologics company focused on developing truly next-generation antibody therapies, and with assets in-licensed from top academic institutions.


TCRyption is a preclinical company focussed on the development of novel approaches to TCR based cellular therapy for cancer and other indications.  Leveraging a unique platform designed to rapidly clone physiologically relevant TCRs, TCRyption seeks to develop a pipeline of product candidates that can treat cancer type and patient populations that are underserved by current approaches.